173 related articles for article (PubMed ID: 20571355)
21. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
23. [Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
Yuan ZG; Hou J; Zhou F; Fu WJ; Chen YB; Xi H; Yang SL
Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):653-5. PubMed ID: 17343194
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
Badros AZ; Goloubeva O; Rapoport AP; Ratterree B; Gahres N; Meisenberg B; Takebe N; Heyman M; Zwiebel J; Streicher H; Gocke CD; Tomic D; Flaws JA; Zhang B; Fenton RG
J Clin Oncol; 2005 Jun; 23(18):4089-99. PubMed ID: 15867202
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
[TBL] [Abstract][Full Text] [Related]
28. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
29. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
30. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
[TBL] [Abstract][Full Text] [Related]
31. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
33. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
35. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
Reece DE; Rodriguez GP; Chen C; Trudel S; Kukreti V; Mikhael J; Pantoja M; Xu W; Stewart AK
J Clin Oncol; 2008 Oct; 26(29):4777-83. PubMed ID: 18645194
[TBL] [Abstract][Full Text] [Related]
36. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
Madden T; Tran HT; Beck D; Huie R; Newman RA; Pusztai L; Wright JJ; Abbruzzese JL
Clin Cancer Res; 2000 Apr; 6(4):1293-301. PubMed ID: 10778954
[TBL] [Abstract][Full Text] [Related]
37. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Moulder S; Dhillon N; Ng C; Hong D; Wheler J; Naing A; Tse S; La Paglia A; Dorr R; Hersh E; Boytim M; Kurzrock R
Invest New Drugs; 2010 Oct; 28(5):634-40. PubMed ID: 19499186
[TBL] [Abstract][Full Text] [Related]
39. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
